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INTRODUCTION
Spasticity is a symptom that describes involuntary muscle hyperactivity in the presence of central
paresis due to several neurological conditions (1). It can consist of various clinical forms, and it has
been reported (2, 3) that spasticity showed a prevalence of 28–38% in patients with stroke, 41–66%
in patients with multiple sclerosis, 13% in patients with traumatic brain injury, and up to 80% of
children with cerebral palsy.
Spasticity can affect quality of life, impair function and heighten economic burden (4, 5), and
it could be associated with several complications, including contractures, pain, fall risk, pressure
ulcers, and infections (6). In addition, caregivers of patients affected by spasticity are more likely to
experience anxiety and depression (7).
Spasticity management aims to reduce its negative impact on patients and carers and to
prevent irreversible soft-tissue changes and tendon contractures by maintaining muscle length and
normalizing limb positioning (8, 9).
Identifying and treating clinically relevant spasticity is key to decreasing patients’ impairments
(10, 11). Interventions must be tailored to meet the problems faced by the person and their goals,
including focal (e.g., chemodenervation with Botulinum Toxin, chemical neurolysis) and general
treatments (e.g., oral antispasticity drugs, cannabinoids, intrathecal baclofen) (10, 11). Besides,
a multidisciplinary team including doctors, physiotherapists, occupational therapists and nurses,
is required: in fact, other physical modalities can optimize the effect of pharmacologic treatment
(e.g., stretching, splinting, postural management, exercise, electrical stimulation, casting, splinting,
extracorporeal shock waves, body vibration) (10, 12).
Noteworthy, it should be pointed out that patients affected by spasticity require periodic access
to the health care facilities.
In particular, Intrathecal baclofen infusion (ITB) systems, proposed in case of severe generalized
spasticity, imply a close follow-up for safety purposes; notably, ITB pump refill is a programmed
procedure that requires regularity in its execution, and that cannot be postponed due to the risk of
withdrawal symptoms (13).
Again, Botulinum toxin Type A (BoNT-A), the gold standard for focal spasticity treatment,
requires a regular administration (every 3–6 months) in order to maintain the clinical effect (14);
moreover, BoNT-Amust be proposed by amultidisciplinary team, since optimal treatment involves
physical therapy in conjunction with intermittent pharmacological treatment (14, 15).
It is well-known that when spasticity worsens, patients may experience a variety of symptoms
(10). In particular, prolonged suspension can potentially accelerate the morphological alterations
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connected with spasticity (e.g., myotendinous and joint
contractures, pain) which could potentially cause a long-term
negative impact on the patients’ level of activity and participation,
as well as to a deterioration in their quality of life (8, 9).
The recent reorganization of non-urgent clinical activities,
connected to the emergency generated by the COVID-19
pandemic, has also significantly involved the treatment of
patients with spasticity.
As per institutional indications, most of these activities have
been suspended or postponed (16, 17).
This situation, necessary in consideration of the pandemic,
has nevertheless exposed patients suffering from spasticity to
the risks connected to the interruption of the treatment as
described above.
Based on these considerations, it seems reasonable to continue
planning the spasticity treatment, carefully monitoring those that
cannot be delayed.
However, several factors must be taken into account to
guarantee both patients’ necessary care and indications for
minimizing a further spread of the pandemic.
For this purpose, an ad-hoc treatment protocol is summarized
in the next section.
CLINICAL RECOMMENDATIONS
Some of these aspects are part of the general indications for
patients’ access to healthcare facilities (18). Still, some specific
elements must consider the patients’ characteristics (19) and the
specific settings where the treatments are carried out (16, 17).
Inpatient Facilities
In this case, spasticity treatment is part of the rehabilitation
program of the patient hospitalized for this purpose.
The hospital organization must consider the general
indications for the containment of the infection (18, 20);
therefore, all the appropriate procedures must be put in place to
avoid exposing the patient to the risk of contracting COVID-19
(21), and in particular:
- adequate clinical monitoring of patients to identify clinical
signs of potential COVID-19 onset (18)
- adequate use of personal protective equipment (PPE)
about the procedures and clinical characteristics of the
patients (18, 22, 23)
- monitoring of the health status of involved staff (18)
- training of staff and patients on compliance with hygiene
rules (18)
- availability and easy retrieval of suitable indications (e.g.,
explanatory material distributed in hospital areas) and
material (e.g., hand sanitizing gel) (18)
- blocking (or severe limitation) of access to visitors (18).
Outpatient Facilities
In this case, since the patient’s access to the hospital or outpatient
facility takes place from the outside, it is necessary to consider
a series of procedures to ensure the safety of the patient and
operators (24).
In particular, several aspects must be considered (Figure 1).
Patient Selection
• in consideration of current government indications (25), it
remains a rule of good clinical practice to limit access to only
patients for whom the treatment cannot be postponed (e.g.,
repetition of treatment with BoNT-A for significant reduction
of autonomy consequent to the recovery of spasticity; ITB refill
or follow up) (26)
• the use of telephone screening tools that allow remote pre-
assessment is recommended to coordinate patient access to
facilities: this is to facilitate the assessment of the patient’s
clinical needs and to monitor any presence of suggestive
symptoms of COVID-19 or to identify any contact with other
affected subjects; for this purpose, video call tools, where
available, can also be supportive for an initial, albeit limited,
clinical evaluation (17, 24).
• Alternatively, in this perspective, progressive implementation
of suitable tools (video call programs, the supply of motion
sensors) that can support the clinical evaluation remotely by
the clinician is desirable, to monitor the situation of patients
by reducing the number of accesses at health facilities; for
this purpose, it is necessary to use the available technological
resources to identify the most suitable tools. At the same
time, it is also necessary to guarantee proper classification and
financial rewards of these services (27).
• in case of previous BoNT-A treatment (14), we suggest
considering a clinical assessment in the health facility if two
or more of these issues are present at screening:
– Last inoculation date with BoNT-A > 3 months (yes/no)
– Increased spasticity in the muscles previously treated
with BoNT-A, which can affect the patient’s function or
autonomy (yes/no)
– Presence of hypertonus in untreated muscles, which can
affect the patient’s function or autonomy (yes/no)
– Severe degree of spasticity conditioning a potential
risk of long-term damage (e.g., myotendinous
retractions) (yes/no)
– Significant presence of pain, potentially related to
spasticity (yes/no)
– Impossibility of wearing orthoses/aids in use due to the
presence of spastic hypertonicity (yes/no).
• We also suggest to carefully consider each of the above-
reported points on patients treated with ITB due to
the potentially life-threatening risk of pump emptying or
malfunction (13).
Access to the Health Facility
• Set a screening station at the entrance to identify subjects
potentially affected by COVID-19 (e.g., targeted medical
history, contactless temperature measurement) to minimize
the risk of exposure to COVID-19; prepare an adequate
clinical pathway in case of suspected infection (e.g., SARS-
COV-2 swab test, according to the local guidelines) (18, 24)
• verify that all staff are trained to recognize possible
clinical signs compatible with COVID-19 and that
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FIGURE 1 | Outpatient management of spasticity treatment.
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FIGURE 2 | Personal Protection Equipment (PPE) management: risk assessment related to the procedure and patient characteristics.
they can provide the correct indications to the
patient (18).
Health Service Provision
• The provision must be adapted to the general indications (24),
with attention to specific aspects of the treatment of patients
affected by spasticity.
• It may be necessary to remodel the interventions’ planning to
allow the implementation of all the appropriate procedures.
In particular, patients must be properly scheduled in order to
avoid gatherings of people (24)
• Reorganization of waiting rooms (18, 24, 28, 29):
– prepare the presence of information panels relating to
COVID-19, highlighting the standards to be respected
– prepare the presence of tools such as hand wash gel and
disposable tissues
– there must be as few people as possible in this area: where
necessary, the service provision must be re-modulated. In
particular, access to carers must be limited
– consider the adaptation of common areas to allow an
adequate spacing of patients (>1m) (28).
Adaptation of Treatment Procedures
• Considering the need to distance patients, the possible use
of PPE with relative dressing/undressing procedures and the
time required for the room cleaning, it is reasonable to set an
agenda with scheduled appointments adapted to these needs
(18, 22, 23)
• the use of correct PPEmust be planned based on the scheduled
procedure and the characteristics of each patient (Figure 2);
in consideration of the potential risk of contagion even in
asymptomatic subjects, the use of a surgical mask by both the
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healthcare professional and the patient is mandatory to limit
the spread of the virus (18, 22, 23)
• strict observance of the usual hygiene rules (e.g., hand
washing) is necessary to minimize the risk of virus
transmission (18, 28–30)
• cleaning and sanitizing of instrumentation and environments
are mandatory (18):
– the environmental sanitation procedures must be
implemented as per institutional or company indications
by the dedicated staff, equipped with the appropriate PPE
– in general, surfaces frequently touched by a large number of
people (such as doorknobs, chairs, desks) must be cleaned at
least daily and if possible more frequently; the use of regular
detergents can be considered sufficient if there has been no
contact with confirmed or suspected COVID-19 patients
– However, it is conceivable to arrange additional cleaning
of the surfaces and devices used during the procedures
between one patient and another (e.g., ultrasound or
electrical stimulation devices in injections with botulinum
toxin, examination table). For this purpose, after removing
any visible traces, a suitable product should be used
wherever possible. Current evidence suggests (31) the use
of a standard detergent associated, where possible, with
a virucidal product or sodium hypochlorite 0.05% or
ethanol 70%
– the use of disposable devices that avoid contamination
of the devices is desirable (e.g., probe cover when using
ultrasound for injection procedures with BoNT-A).
Adaptation of Areas for Rehabilitation (if Applicable)
As previously stated, spasticity treatment requires
multidisciplinary management. In particular, adjunctive
treatment might improve the clinical effect of BoNT-A, and they
should be applied in the health care facility immediately after the
BoNT-A injection (12).
However, in order to minimize the risk during COVID-19
pandemic, several issues must be carefully considered:
• it must be highlighted that the screening procedures must be
implemented at each access to the facility (24)
• we suggest that the rules of distancing between
patients (>1m) (28) must also be applied in the
organization of the areas where the patient’s rehabilitation
treatment takes place (e.g., gyms, areas dedicated to the
occupational therapy)
• the correct use of PPE for the staff involvedmust be considered
based on the patient’s characteristics (18, 22, 23)
• consider information panels and provide suitable material
(e.g., hand wash gel) within the area (18, 24)
• prepare adequate plans for cleaning and sanitizing rooms and
tools; in particular, attention must be paid to cleaning the
equipment used by patients (e.g., electrical stimulation devices,
dedicated equipment, and machinery, beds) (18, 31)
• if appropriate, exposure risk should be limited by
implementing communication technologies which can
support remote rehabilitation treatment (27, 32).
CONCLUSIONS
The treatment of the patients suffering from spasticity,
while not showing the characters of urgency except
for some procedures such as ITB refill or monitoring,
is worthy of particular attention in this phase of the
COVID-19 pandemic.
It must be highlighted that this prolonged suspension of
deferred activities has potentially exposed many patients to the
disabling consequences of untreated spasticity.
Given these aspects, close monitoring of patients is
recommended in order to plan an adequate schedule for
the resumption of patients’ treatment, in compliance with the
rules for reducing the spread of the COVID-19 pandemic.
The use of remote assessment tools can support the
identification of patients who require treatment in a short time
to prevent the onset of complications that may further limit their
level of activity and participation.
Looking ahead and considering the foreseeable need to adopt
these precautions in the medium term, using these technologies
can also allow adequate planning of patients’ follow-up and
rehabilitation treatment.
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